Director James M. Daly to resign from Halozyme board at end of 2023

HALOZYME THERAPEUTICS, INC.

James M. Daly notified Halozyme of his resignation from the Board, effective December 31, 2023.
Resignation is not due to any disagreement with the Company, its operations, strategy, management, or Board.
Mr. Daly's departure is planned nearly a year in advance, allowing for orderly succession.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

James M. Daly

Director

HALO · HALOZYME THERAPEUTICS, INC.

Effective: 2023-12-31
Filed: February 23, 2023, 6:59 PM ET

On February 22, 2023, James M. Daly, a member of the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”), notified the Company of his intention to resign from the Company’s Board of Directors effective at the end of the 2023 calendar year.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James M. Daly resigned as Director at HALOZYME THERAPEUTICS, INC..

Action: resigned
Role: Director

Exact text from the filing

On February 22, 2023, James M. Daly, a member of the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”), notified the Company of his intention to resign from the Company’s Board of Directors effective at the end of the 2023 calendar year.

View on SEC.gov

HALOZYME THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001159036-23-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.